2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Immunotherapy, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Inherited Marrow Failure Syndromes, Aplastic Anemia, Genetic Disorders, Immunology, Autoimmune Hemolytic Anemia, Neutropenia, Infectious Diseases, Viral, Bacterial, Fungal, Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant, Young Adult
PAPER

6221 Time to first antibiotic and weekend admission in febrile neutropenia: Association with in-hospital mortality and readmission in a multicenter cohort

Aakriti Adhikari, MD, Emma Kaz Frick, MS, MAEd2, Yahia Mohamed, PhD3, An-Lin Cheng, PhD4, Suman Suman, PhD5, Tamara McMahon, MIS6, Anuj Shrestha, MD, FACP7
1 University of Missouri-Kansas city, Kansas City, Missouri, United States
2 University of Missouri-Kansas city, Kansas City, Missouri, United States
3 University of Missouri-Kansas city, Kansas City, Missouri, United States
4 University of Missouri-Kansas city, Kansas City, Missouri, United States
5 University of Missouri-Kansas city, Kansas City, Missouri, United States
6 University of Missouri-Kansas city, Kansas City, Missouri, United States
7 University of Missouri-Kansas city, Kansas City, Missouri, United States

Background
Giving broad-spectrum antibiotics right away is the standard of care for febrile neutropenia (FN), but how treatment delays actually affect outcomes in day-to-day practice is still not well characterized. Weekend admission has also been linked to worse outcomes across several acute illnesses. We looked at antibiotic timing and weekend admission together in a large multicenter cohort to see how each related to mortality and readmission.

Methods
This was a retrospective cohort study using the Cerner Health Facts Database, a deidentified multicenter electronic health record database. We identified adult FN encounters using ICD-9-CM and ICD-10-CM diagnosis codes and grouped time from admission to first antibiotic administration into four categories: under 4 hours, 4 to 12 hours, 12 to 24 hours, and over 24 hours. Weekend admission was analyzed as its own exposure. Encounters with invalid admission or discharge timestamps were excluded using the database's validity indicators. We used multilevel logistic regression clustered by hospital to evaluate in-hospital mortality and 30- and 60-day all-cause readmission.

Results
The cohort included 32,907 encounters across 27,498 patients. Mean age was 59 ± 17 years, and 51.3% were male. Most encounters (93.9%) received antibiotics within 4 hours; 5.6% fell into the 4 to 12 hour window, and delays beyond that were rare, at 0.4% for 12 to 24 hours and 0.1% beyond 24 hours. Weekend admissions made up 37.7% of the cohort. In-hospital mortality was 7.0% overall, with 30- and 60-day readmission rates of 6.0% and 9.0%.

Even a modest delay mattered. Compared with antibiotics given within 4 hours, a 4 to 12 hour delay was independently associated with higher odds of in-hospital mortality (OR 1.48, 95% CI 1.02 to 2.16). Mortality trended higher still beyond 12 hours, but those groups were too small for a reliable estimate (n=121 and n=23). Weekend admission did not affect mortality, but it was independently associated with higher 30-day readmission (OR 1.11, 95% CI 1.00 to 1.24).

Conclusions
Most patients with FN in this cohort received antibiotics fast, within four hours, as guidelines recommend. Still, even the shift from under 4 hours to 4 to 12 hours carried a real mortality signal. Weekend admission did not affect in-hospital death but was tied to a higher chance of returning to the hospital within 30 days. These findings support continued efforts to keep antibiotic administration timely and to strengthen care transitions for patients hospitalized with FN.

Limitations
Diagnoses were identified using administrative codes rather than manual chart review. Granulocyte colony-stimulating factor exposure could not be reliably captured because of inconsistent CPT coding and was not included in the analysis.

Aakriti Adhikari, MD: No relevant conflicts of interest to declare.